Home » EU Ombudsman Asks EMA to Improve Transparency
EU Ombudsman Asks EMA to Improve Transparency
May 18, 2010
The European Medicines Agency (EMA) should review a 2008 citizen request for information on adverse drug reactions (ADRs) associated with a popular acne drug and take steps to make the reports publicly available, EU Ombudsman Nikiforos Diamandouros said in a May 10 draft recommendation.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor